Skip to content

REIMAGINE

Asthma Symptoms and Signs | Pulmonary Disorders

This study is being done to better understand how well the medication mepolizumab (NUCALA) is working in routine medical practice to treat a sub-population of adult patients with severe asthma who have what is termed an eosinophilic phenotype (SA-EP). Mepolizumab is approved (marketed drug) in Canada.

Study participants will be asked to complete questionnaires and lung function testing in addition to their standard of care visit.

Participation in the study will last 2 years.

null

Conditions de participation

  • Sexe:

    Male, Female, Intersex

  • Âges admissibles:

    18 to 80

Critères de participation

Inclusion Criteria:
You might be eligible if:
1) 18 years or over
2) You have severe asthma with an eosinophilic phenotype
3) You have been prescribed NUCALA
Exclusion Criteria:
You may not be eligible if:
1) Under the age of 18
2) You do not have severe asthma with an eosinophilic phenotype
3) You are pregnant
4) You are a current smoker

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: REB24-0130